High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
Shpall
E J
EJ
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Clarke-Pearson
D
D
Soper
J T
JT
Berchuck
A
A
Jones
R B
RB
Bast
R C
RC
Ross
M
M
Lidor
Y
Y
Vanacek
K
K
Tyler
T
T
D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D016026:Bone Marrow Transplantation; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000628:therapy*; D013852:Thiotepa / Q000627:therapeutic use; D014182:Transplantation, Autologous
D000477:Alkylating Agents; D015295:Antigens, Tumor-Associated, Carbohydrate; D003520:Cyclophosphamide; D013852:Thiotepa; D002945:Cisplatin